HIV-1 Salvage Therapy Can Omit NRTIs and Remain Efficacious and Safe
People with HIV-1 infection who have virologic failure can safely omit nucleoside reverse transcriptase inhibitors (NRTIs) in new regimens that include > 2 active drugs.
People with HIV-1 infection who have virologic failure can safely omit nucleoside reverse transcriptase inhibitors (NRTIs) in new regimens that include > 2 active drugs.
Reduction in HIV-1 RNA level significantly greater for fostemsavir versus placebo in randomized cohort.
Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.
Results from the DUALIS study demonstrated that dual therapy with dolutegravir and boosted darunavir tended to be an effective treatment option with no treatment-emergent resistance for people with HIV.
Therapy with monthly injection of long-acting cabotegravir plus rilpivirine was noninferior to once-daily oral therapy for maintaining HIV-1 suppression.
Symtuza is a 4-drug combination of darunavir, an HIV-1 protease inhibitor; cobicistat, a CYP3A inhibitor; and emtricitabine and tenofovir alafenamide.
Research has identified 3 approaches that may satisfactorily predict serum neutralization of HIV infection and may result in more efficient use of serum samples identified.
The gold salt auranofin may be a promising addition to antiretroviral therapy (ART) to target individuals categorized as latent viral reservoirs of HIV-1.
The NDA for a first-in-class HIV-1 attachment inhibitor for the treatment of HIV-1 infection has been submitted to the FDA.
Expanding access to PrEP is key part of government’s aim of ending nation’s HIV epidemic by 2030